Member of Lyonbiopole
ErVimmune develops breakthrough immunotherapies based on the identification of non-conventional tumor antigens shared across tumors and patients.
ErVimmune identifies & targets viral remnants (HERVs) in tumors, shared across patients, thanks to proprietary bioinformatic algorithms allowing an AI-powered selection to ensure potent & safe tumor targeting.
Our initial targeted indication is triple negative breast cancer (TNBC) with PoC demonstrating the ability of HERV-specific T-cells to recognize and eliminate TNBC cells, with strong backing from FDA/EMA and major publications.
Application market: Oncology
Type of activity: Therapeutics, Pharma or Biotech
Technologies: Cell Therapy - Stem cells - Cell Biology - Biobanking, Immunotherapy, Vaccine
Created on oct. 1st, 2019 - 12 employees
Address
Centre Léon Bérard
28 rue Laennec
Bâtiment Cheney A 69008 Lyon
Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.